AUTODOC
26.3.2020 18:38:07 CET | Business Wire | Press release
Autodoc, Europe’s largest online retailer of car spare parts, is donating EUR 50,000 to the Stiftung Universitätsmedizin Essen foundation to support the fight against COVID-19. The researchers are studying the biology of the virus together with Chinese colleagues in a laboratory in Wuhan, China. The aim is to develop therapeutic options and preventive measures. As an internationally active company, Autodoc would like to become involved at a global level in the fight against the current pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005597/en/
Autodoc GmbH, based in Berlin, is an international company with online shops in 26 European countries. The employees come from all over the world. The current crisis also affects Autodoc employees, customers and suppliers to a high degree. Autodoc would like to take its responsibility as a company and actively participate in the fight against COVID-19. To this end, Autodoc is supporting researchers at the Universitätsmedizin Essen medical center and the Union Hospital in Wuhan in their search for special treatments against the virus.
According to Alexej Erdle, managing partner of Autodoc GmbH, “The corona crisis is a global pandemic that affects us all. We are an international company. That is why we feel a clear responsibility here to contribute to solving this crisis. Every day we see what can be achieved when people from different countries work together, just as the researchers from Essen and Wuhan are doing. Supporting their work is now the best way for us to do something that helps people all over the world, i.e. to fight this pandemic. With this donation, we want to set an example so that every individual as well as every company can think about how to get involved within the scope of their respective possibilities so that we can succeed in overcoming this challenge together.
Researchers against a global pandemic
Since the end of December 2019, the novel coronavirus, SARS-CoV-2, has been spreading at high speed. It is the trigger of the COVID-19 disease. The Institute of Virology and the Clinic for Infectiology at the Universitätsmedizin Essen medical center and the Clinic for Infectious Diseases at the Union Hospital in Wuhan have been working closely together for many years. In 2017, a joint research laboratory was founded in Wuhan. Numerous data and samples have been collected and recorded there since the beginning of the COVID-19 pandemic. Due to the number of cases in China, this results in a much larger database than is currently the case in Germany, for example. The laboratory is already in operation and well equipped, but money is still urgently needed to cover the running costs for material and personnel. Autodoc is now supporting the researchers’ work with a sum of EUR 50,000.
Jorit Ness, Managing Director of the University Medical Foundation, is very grateful for the support: “In the current situation, rapid help – which is at the same time sustainable – is essential. Thanks to the research cooperation between Essen and Wuhan, which has been in place for years, professional and established structures are now in place and can be used immediately. It is now important to make additional funds available for the evaluation of the extraordinarily large amounts of data and samples of disease cases. With the donation from Autodoc GmbH we have come a big step closer to our goal”.
Social commitment
Since its foundation in 2008, Autodoc has seen itself as an active part of society and is committed both ideologically and financially to helping disadvantaged social groups. Autodoc therefore regularly supports local initiatives in various European countries.
If you would like to support the research work in Essen and Wuhan, please visit https://www.universitaetsmedizin.de/forschung/corona/ and make a donation online. Or donate directly to:
Stiftung Universitätsmedizin Essen
Hufelandstraße 55
45147 Essen, Germany
E-mail: info@universitaetsmedizin.de
Internet: https://www.universitaetsmedizin.de/
Donation account:
IBAN: DE 0937 0205 0005 0005 0005
BIC: BFSWDE33
Reference: corona research
Autodoc GmbH – a brief profile
Autodoc GmbH is Europe’s leading online dealer for automotive spare parts. As the fastest-growing company in this sector with a 63% growth in turnover in the 2018 financial year to around EUR 415 million (2017: EUR 254 million), Autodoc is aiming to further expand its position. Thanks to its successful expansion, Autodoc is now represented in 25 other European countries in addition to Germany. Autodoc pursues a strong customer focus through social media activities, technical support in the respective national language and demand-oriented product range composition with currently almost 2.5 million products from 545 brand manufacturers for 128 car brands. The online retailer offers a wide range of products from brake systems, body parts, shock absorbers and springs, exhaust systems, interior elements, steering systems and clutches to air conditioning systems, heaters, repair kits and engine oil. In June 2018, the company celebrated its tenth anniversary. Autodoc GmbH is based in the Berlin district of Lichtenberg and is fully owner-managed. In May 2019, the company opened a representative office on Kurfürstendamm in addition to its headquarters.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005597/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release
We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release
Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
